HIGHLIGHTS First human dosing of PlexarisTM has occurred in Exopharm’s PLEXOVAL Study PLEXOVAL is a world-first study using a cell free...
A leading developer of exosome therapies, Australia-based Exopharm Limited, supports the US Food & Drug Administration (FDA) in highlighting...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.